Triple Negative Breast Neoplasms

"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Descriptor ID	D064726
MeSH Number(s)	C04.588.180.788 C17.800.090.500.788
Concept/Terms	Triple Negative Breast Neoplasms Triple Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Neoplasms ER Negative PR Negative HER2 Negative Breast Neoplasms Triple-Negative Breast Cancer Breast Cancer, Triple-Negative Breast Cancers, Triple-Negative Triple-Negative Breast Cancers Triple-Negative Breast Neoplasm Breast Neoplasm, Triple-Negative Breast Neoplasms, Triple-Negative Triple Negative Breast Neoplasm Triple-Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Cancer ER Negative PR Negative HER2 Negative Breast Cancer Triple Negative Breast Cancer

Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Breast Neoplasms [C04.588.180]
Triple Negative Breast Neoplasms [C04.588.180.788]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Breast Diseases [C17.800.090]
Breast Neoplasms [C17.800.090.500]
Triple Negative Breast Neoplasms [C17.800.090.500.788]

Below are MeSH descriptors whose meaning is related to "Triple Negative Breast Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.

Bar chart showing 18 publications over 6 distinct years, with a maximum of 5 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	2	0	2
2015	3	1	4
2016	5	0	5
2017	2	0	2
2019	1	0	1
2020	4	0	4

Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.

Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precis Oncol. 2022 04; 6:e2100463.

View in: PubMed
MacCuaig WM, Thomas A, Claros-Sorto JC, Gomez-Gutierrez JG, Alexander AC, Wellberg EA, Grizzle WE, McNally LR. Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent. Biotech Histochem. 2022 Jan; 97(1):1-10.

View in: PubMed
Vranic S, Gatalica Z. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. Clin Breast Cancer. 2022 06; 22(4):e576-e585.

View in: PubMed
Hong DS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.

View in: PubMed
Yuan Y, Pan K, Mortimer J, Chlebowski RT, Luo J, Yan JE, Yost SE, Kroenke CH, Adams-Campbell L, Nassir R, Sun Y, Shadyab AH, Vitolins MZ, Saquib N, Wild RA, Manson JE, Nelson RA. Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer. 2021 05 15; 127(10):1658-1667.

View in: PubMed
Grant CV, Cai S, Risinger AL, Liang H, O'Keefe BR, Doench JG, Cichewicz RH, Mooberry SL. CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells. J Nat Prod. 2020 10 23; 83(10):3080-3092.

View in: PubMed
Westcott JM, Camacho S, Nasir A, Huysman ME, Rahhal R, Dang TT, Riegel AT, Brekken RA, Pearson GW. ?Np63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion. Cancer Res. 2020 09 15; 80(18):3933-3944.

View in: PubMed
Pederson PJ, Cai S, Carver C, Powell DR, Risinger AL, Grkovic T, O'Keefe BR, Mooberry SL, Cichewicz RH. Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from Calotropis gigantea. J Nat Prod. 2020 07 24; 83(7):2269-2280.

View in: PubMed
Kil YS, Risinger AL, Petersen CL, Mooberry SL, Cichewicz RH. Leucinostatins from Ophiocordyceps spp. and Purpureocillium spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer. J Nat Prod. 2020 06 26; 83(6):2010-2024.

View in: PubMed
Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019 Aug 20; 19(3):227-233.

View in: PubMed

People

Explore

Similar Concepts

Top Journals